|
- The sponsored study with a relative risk of 1.5 has been reanalysed
several times, yielding lower relative risks; after this failed to
convince, a new reanalysis was sponsored by another company.
- One sponsored study finding an increased risk has not been published.
- Vandenbroucke JP, Helmerhorst FM, Frits R Rosendaal FR. Competing
interests and controversy about third generation oral contraceptives. BMJ
2000; 320: 381.
|